REG - State Street Global Shire plc Takeda Pharma.Co.Ltd - Form 8.3 - Shire plc

Takeda Pharmaceutical CoAnnouncement

20/08/2018 14:25

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180817:nRSQ3269Ya

RNS Number : 3269Y
State Street Global Advisors
20 August 2018
 
RNS No: 2030Y
 
Date: 20-Aug-2018
 
Due to change in holdings and transaction the document is replaced.
 
FORM 8.3
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 
 (a) Full name of discloser:                                                      State Street Global Advisors & Affiliates
 (b) Owner or controller of interests and short positions disclosed, if
 different from 1(a):
      The naming of nominee or vehicle companies is insufficient.  For a
 trust, the trustee(s), settlor and beneficiaries must be named.
 (c) Name of offeror/offeree in relation to whose relevant securities this form
 relates:
                                                                                Shire plc
      Use a separate form for each offeror/offeree
 (d) If an exempt fund manager connected with an offeror/offeree, state this
 and specify identity of offeror/offeree:
      (e)           Date position held/dealing undertaken:
      For an opening position disclosure, state the latest practicable date       16-August-2018
 prior to the disclosure
 (f)  In addition to the company in 1(c) above, is the discloser making           YES / NO / N/A
 disclosures in respect of any other party to the offer?
                                                                                If YES, specify which:
      If it is a cash offer or possible cash offer, state "N/A"
                                                                                  Yes - Takeda Pharmaceutical Company Limited
 
2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE
 
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
 
(a)        Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following the dealing
(if any)
 
 Class of relevant security:                                          5p Ordinary - 22,407,936 Shares
                                                                      ADR - 60,283 Shares (1 ADR = 3 ordinary shares)
                                                                      Interests                     Short positions
                                                                      Number         %              Number         %
 (1) Relevant securities owned and/or controlled:                     22,588,785     2.47023%
 (2) Cash-settled derivatives:
 (3) Stock-settled derivatives (including options) and agreements to
 purchase/sell:
                                                                      22,588,785     2.47023%
      TOTAL:
 
The change in the holding of 1,835 shares since the last disclosure for
dealing 15 August 2018 is due to the transfer in of a discretionary holding.
 
All interests and all short positions should be disclosed.
 
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
 
(b)        Rights to subscribe for new securities (including directors'
and other employee options)
 
 Class of relevant security in relation to which subscription right exists:
 Details, including nature of the rights concerned and relevant percentages:
 
 
3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
 
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1©, copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales
 
 Class of relevant security  Purchase/sale  Number of securities  Price per unit
 5p Ordinary                 Purchase       25,677                GBP 44.43
 5p Ordinary                 Purchase       1,407                 GBP 44.153497
 5p Ordinary                 Sale           5,379                 GBP 44.43
 5p Ordinary                 Sale           232,076               GBP 44.25
 
 (b)       Cash-settled derivative transactions
 
 Class of relevant security  Product description  Nature of dealing                                                              Number of reference securities  Price per unit
                             e.g. CFD             e.g. opening/closing a long/short position, increasing/reducing a long/short
                                                  position
 
(c)        Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 
 Class of relevant security  Product description e.g. call option  Writing, purchasing, selling, varying etc.  Number of securities to which option relates  Exercise price per unit  Type                           Expiry date  Option money paid/ received per unit
                                                                                                                                                                                      e.g. American, European etc.
 
(ii)        Exercise
 
 Class of relevant security  Product description  Exercising/ exercised against  Number of securities  Exercise price per unit
                             e.g. call option
 
(d)        Other dealings (including subscribing for new securities)
 
 Class of relevant security  Nature of dealing               Details  Price per unit (if applicable)
                             e.g. subscription, conversion
 
4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 
 Details of any indemnity or option arrangement, or any agreement or
 understanding, formal or informal, relating to relevant securities which may
 be an inducement to deal or refrain from dealing entered into by the person
 making the disclosure and any party to the offer or any person acting in
 concert with a party to the offer:
 Irrevocable commitments and letters of intent should not be included.  If
 there are no such agreements, arrangements or understandings, state "none"
 None
 
(b)        Agreements, arrangements or understandings relating to
options or derivatives
 
 Details of any agreement, arrangement or understanding, formal or informal,
 between the person making the disclosure and any other person relating to:
 (i)  the voting rights of any relevant securities under any option; or
 (ii) the voting rights or future acquisition or disposal of any relevant
 securities to which any derivative is referenced:
 If there are no such agreements, arrangements or understandings, state "none"
 None
 
(c)        Attachments
 
 Is a Supplemental Form 8 (Open Positions) attached?            No
 
 Date of disclosure:  20-August-2018
 Contact name:        Chetan Shah
 Telephone number:    020 33956564
 
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service and must also be emailed to the Takeover Panel at
monitoring@disclosure.org.uk (mailto:monitoring@disclosure.org.uk) .  The
Panel's Market Surveillance Unit is available for consultation in relation to
the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.